<DOC>
	<DOC>NCT00155714</DOC>
	<brief_summary>The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension</brief_summary>
	<brief_title>Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension</brief_title>
	<detailed_description>Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil. Efficacy of inhaled NO and Iloprost will also be compared.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Phosphodiesterase Inhibitors</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients with primary and secondary pulmonary arterial hypertension Unstable patients or patients with allergy to sildenafil</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>type-5 phosphodiesterase Inhibitors</keyword>
	<keyword>Sildenafil</keyword>
</DOC>